These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7514473)

  • 1. [Prognostic factors in prostate cancer. Review of the literature and future perspectives].
    Cussenot O; Ravery V; Desgrandchamps F; Cochand-Priollet B; Teillac P; Le Duc A
    Prog Urol; 1994 Feb; 4(1):17-30. PubMed ID: 7514473
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumour markers in monitoring the treatment of advanced prostate cancer.
    Cooper EH; Armitage TG
    Prog Clin Biol Res; 1990; 359():65-72; discussion 73-4. PubMed ID: 1704634
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 4. Substaging pathologically organ confined (pT2) prostate cancer: an exercise in futility?
    van der Kwast TH
    Eur Urol; 2006 Feb; 49(2):209-11. PubMed ID: 16417961
    [No Abstract]   [Full Text] [Related]  

  • 5. The evolving role of familial history for prostate cancer.
    Colloca G; Venturino A
    Acta Oncol; 2011 Jan; 50(1):14-24. PubMed ID: 20874046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invited commentary: Prostate cancer: doing less might be more. Comment on "Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer".
    Ablin RJ; Sartor O; Bennett CL
    Arch Intern Med; 2010 Aug; 170(15):1397-9. PubMed ID: 20696969
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives.
    Srigley JR; Amin M; Boccon-Gibod L; Egevad L; Epstein JI; Humphrey PA; Mikuz G; Newling D; Nilsson S; Sakr W; Wheeler TM; Montironi R
    Scand J Urol Nephrol Suppl; 2005 May; (216):8-19. PubMed ID: 16019756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis of prostate cancer].
    Strittmatter F
    MMW Fortschr Med; 2010 May; 152(19):40-2. PubMed ID: 20557001
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessing risk: does this patient have prostate cancer?
    Carter HB
    J Natl Cancer Inst; 2006 Apr; 98(8):506-7. PubMed ID: 16622114
    [No Abstract]   [Full Text] [Related]  

  • 11. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
    Stephan C; Schnorr D; Loening SA; Jung K
    Eur Urol; 2005 Dec; 48(6):1059-60; author reply 1060-1. PubMed ID: 16260082
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
    J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.
    Moul JW; Connelly RR; Perahia B; McLeod DG
    J Urol; 1998 Mar; 159(3):935-40. PubMed ID: 9474187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer and life insurance.
    Milano AE
    J Insur Med; 2000; 32(2):96-108. PubMed ID: 15912909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
    Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
    Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes.
    Taplin ME; Kantoff PW
    J Clin Oncol; 2003 Oct; 21(19):3552-3. PubMed ID: 12913104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.